NANOBIOTIX : Résulta
NANOBIOTIX : Résultats positifs de la Phase II/III dans les Sarcomes des Tissus Mous avec NBTXR3 présentés à l’ESMO
October 19, 2018 12:05 ET | NANOBIOTIX
NANOBIOTIX : RESULTATS POSITIFS DE LA PHASE II/III DANS LES SARCOMES DES TISSUS MOUS AVEC NBTXR3 PRESENTES A L’ESMO Dr. Sylvie Bonvalot, Chef du Service Sarcomes et Tumeurs Complexes de...
Studieläkemedel till
Studieläkemedel till PledPharmas globala fas III program med läkemedelskandidaten PledOx® levererat
September 28, 2018 02:00 ET | PledPharma AB
Stockholm, 28 september 2018. PledPharma AB (publ) meddelar i dag att studieläkemedlet till det planerade fas III‑programmet med läkemedelskandidaten PledOx® är framgångsrikt färdigproducerat och...
Study drug for the P
Study drug for the PledOx® global phase III program delivered
September 28, 2018 02:00 ET | PledPharma AB
Stockholm, September 28, 2018. PledPharma AB (publ) announces that the PledOx® study drug for the planned phase III program has successfully been produced and delivered. As previously announced,...
Logo_Biofrontera_AG.png
Biofrontera starts patient recruitment for U.S. Phase III Trial Evaluating Ameluz® / BF-RhodoLED® for Superficial Basal Cell Carcinoma
September 26, 2018 03:15 ET | Biofrontera AG
Enrollment of 186 patients at 12 study sites in the U.S. startedPhase III trial completion for photodynamic therapy of superficial basal cell carcinoma expected in first half of 2020Filing for...
gmi 2018.png
Pharmacovigilance Market will register 10.7% CAGR to cross $8.0 billion by 2024: Global Market Insights, Inc.
September 25, 2018 07:00 ET | Global Market Insights, Inc
Sellbyville, Delaware, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Global Pharmacovigilance Market will surpass USD 8.0 billion by 2024; according to a new research report by Global Market Insights, Inc....
Logo-uniQure-MS-Word_Orange.jpg
uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B
June 28, 2018 07:00 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 28, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
20170406 Telix Logo.png
Telix and Isologic conclude manufacturing agreement for North America
June 25, 2018 06:47 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and MONTREAL, June 25, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix Group”, the “Company”), a clinical-stage biopharmaceutical company focused on the...
Japanska läkemedelsm
Japanska läkemedelsmyndigheten (PMDA) ger sitt stöd för en expansion av PledOx® fas III-program till att inkludera japanska patienter
June 13, 2018 02:30 ET | PledPharma AB
Stockholm, 13 juni 2018. PledPharma AB (publ) och deras partner Solasia Pharma K.K. (Solasia) meddelar idag att den japanska läkemedelsmyndigheten (PMDA) som följd av mötet med PledPharma och Solasia,...
Japanese Medical Age
Japanese Medical Agency (PMDA) supports the expansion of the Phase III program for PledOx® to include Japanese patients
June 13, 2018 02:30 ET | PledPharma AB
Stockholm, June 13, 2018. PledPharma AB and Solasia Pharma K.K. (Solasia) today announced that the Japanese Pharmaceuticals and Medical Devices Agency, PMDA, following a meeting with PledPharma and...
GMILogo_Vertical-Gradient.png
Pharmacovigilance Market will secure 10% CAGR to cross $8 billion by 2024: Global Market Insights, Inc.
March 19, 2018 07:00 ET | Global Market Insights, Inc
Sellbyville, Delaware, March 19, 2018 (GLOBE NEWSWIRE) -- Global Pharmacovigilance Market is set to exceed USD 8 billion by 2024; according to a new research report by Global Market Insights....